Luoshi Neiyi prescription (LSNYP) is a traditional Chinese medicine that has a clinical effect on endometriosis (EMs). This study combined network pharmacology with experimental validation to explore its potential molecular …
Endometriosis (EMs), a prevalent disorder characterized by pelvic pain and infertility, affects numerous bodily systems and markedly diminishes life quality. Yiqi Huoxue formula (YQHXF) has demonstrated promising therapeutic efficacy. However, …
Transient Receptor Potential Melastatin 3 (TRPM3) is a non-selective, Ca2+-permeable ion channel that plays a pivotal role in peripheral thermosensation and nociception. Moreover, gain-of-function variants in TRPM3 underlie a spectrum …
This study presents a comprehensive bibliometric assessment of global research on the use of rangeland and wild plants in women's health from 1996 to 2025. A total of 718 publications …
Endometriosis is a gynecological disorder predominantly affecting women of reproductive age and is considered a potential risk factor for the development of endometrial cancer. However, the molecular mechanisms underlying the …
Zishen Quyu Jiedu formula (ZQYJDF) is a commonly used prescription for endometriosis (EMs) with clinical efficacy. However, its active components and potential mechanisms remain unknown. This study aimed to identify …
Endometriosis (EMs) is a persistent inflammatory condition whose three main symptoms, mass, pain, and infertility, severely affect female patients of childbearing age. Hu-Po-San (HPS), a preparation consisting of various herbal …
Endometriosis (EMs) with anxiety/depression is a common comorbidity of EMs, yet effective treatments are still lacking. Leaves of Paeonia suffruticosa Andr. (PSL) have potential therapeutic effects on EMs and their …
This study investigates the mechanism of Ge Xia-Zhu Yu decoction (GXZYT) in the treatment of endometriosis (EMS). The active components and targets of GXZYT were screened using TCMSP database and …
To evaluate the safety and pharmacokinetics/pharmacodynamics of AMY109, an anti-interleukin-8 recycling antibody in a first-in-human phase 1 trial in healthy volunteers (HVs) and patients with endometriosis.